CovInnovations™ Secures Funding For Covid-19 Related Products
CovInnovations™ has secured $480,000 in funding that will be utilized to accelerate the FDA approval process for CovArrest™, the revolutionary new treatment for hospitalized patients with severe COVID-19 symptoms. The company retained Biotech Research Group, a full service regulatory and product development consulting firm, to help guide the FDA-submission process. BRG has an excellent reputation as a leading regulatory and scientific affairs consulting firm, and the company has clients and consultants in more than 60 countries across the globe.
The company also conducted gap reports for multiple products under development, including CovArrest™, CovAssess™ and CovaTest™. CovAssess™ is a dual-marker COVID-19 susceptibility test that we anticipate will be able to measure a person’s chances of catching the Coronavirus and even dying from it. CovaTest™ is an RNA-based rapid test being designed for home use or point-of-care that can determine the presence of COVID-19 and the strain in about two minutes.
CovInnovations™ continues to focus on future go-to-market preparedness for CovArrest™ as it anticipates FDA approval, cultivating relationships with international representatives and clinical partners. Additionally, the company recently met with a pharmacist with 503a pharmacy regarding CovArrest™ and its formulation.
About CovArrest™
This new drug is composed of two current FDA-approved drugs that work synergistically to attack the same disease and are both metabolized by the same liver enzymes. One of the components of CovArrest™ showed significant success in a retrospective review completed in December 2020. This study demonstrated a 68% reduction in mortality (p<0.05) and a 37% reduction in length of hospital stay (p<0.01). The treated group and the control group both received standard of care treatment as of 6/2020. Patients in the group provided the drug had a 93.6% survival rate as compared to the control group which had a survival rate of 78.5%. Those who did not survive appeared to experience a resurgence of viral replication or an insufficiently suppressed immune response, leading to the addition of the second component of CovArrest™. A subsequent cohort of 11 patients with the combined drug achieved 100% survival.
ABOUT CovInnovations™
CovInnovations™ creates technologies and solutions directly related to the COVID-19 pandemic. The company’s patent-pending treatments and technologies seek to create a new standard of care in the battle against this disease. CovInnovations™ products feature groundbreaking technologies that assess, diagnose and treat COVID-19 with the goal of integrating our world back to pre-pandemic times. The company was founded by Dr. Aury Nagy, M.D. FAANS, a neurosurgeon practicing in Las Vegas.
For further information, visit: www.covinnovations.com.
FORWARD LOOKING STATEMENT: Various statements contained in this presentation, including those that express a belief, expectation or intention, as well as those that are not statements of historical fact, are forward-looking statements. These forward-looking statements may include projections and estimates concerning the timing and success of strategies, plans or intentions. We have based these forward-looking statements on our current expectations and assumptions about future events. These assumptions include, among others, our projections and expectations regarding: market trends litigation, our ability to create an opportunity with attractive current yields and upside. While we consider these expectations and assumptions to be somewhat reasonable, they are inherently subject to significant business, economic, competitive, regulatory and other risks, contingencies and uncertainties, most of which are difficult to predict and many of which are beyond our control and could cause actual results to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements. Investors should not place undue reliance on these forward-looking statements. We undertake no obligation to update any forward-looking statements to conform to actual results or changes in our expectations, unless required by applicable law.